New use of Roche's Xeloda OK'd in Japan

• The Japanese Ministry of Health, Labour and Welfare approves the use of Roche's (OTCQX:RHHBY) cancer med Xeloda (capecitabine) tablets for the adjuvant chemotherapy treatment of rectal cancer. The new indication adds to its current labeling for use in certain breast, colon, colorectal and gastric cancers.
• Xeloda is marketed in Japan by Chugai Pharmaceutical (OTCPK:CHGCF)(OTCPK:CHGCY), of which Roche is the majority owner.